SignateraTM MRD Identifies Breast Cancer Patients Who Can Forgo Surgery
Natera’s Signatera circulating‑tumor DNA test was shown in a prospective Clinical Cancer Research study to identify older women (≥70) with early‑stage ER⁺/HER2‑ breast cancer who can safely forgo surgery and remain progression‑free on primary endocrine therapy. Baseline MRD‑negative patients (68% of the cohort) experienced zero progression, delivering a 100% negative predictive value. Among MRD‑positive patients, 64% cleared ctDNA after six months of endocrine therapy, and all seven remained free of distant disease, while the test flagged progression before imaging in every case that later progressed. Over 80% of participants reported that Signatera helped guide treatment decisions without increasing anxiety.
Canopy Growth’s Apollo Cannabis Clinics Named Best Medical Cannabis Clinic
Canopy Growth’s Apollo Cannabis Clinics was voted Best Medical Cannabis Clinic in the 2025 Toronto Star Readers’ Choice Awards, reflecting strong patient trust. The accolade spotlights Apollo’s free, fully virtual consultations that serve Canadians with personalized, evidence‑based treatment for chronic...
Sol-Millennium Medical Inc. Launches U.S. B2B eShop, Providing Direct Access to Safety Engineered Medical Devices Nationwide
Sol‑Millennium Medical Inc. has launched a dedicated U.S. B2B e‑commerce platform, b2b.solm.com, allowing healthcare providers nationwide to purchase its safety‑engineered medical devices directly. The site streamlines registration, pricing visibility, and order placement for settings ranging from physician offices to veterinary...
Bausch + Lomb Will Release First-Quarter 2026 Financial Results on April 29
Bausch + Lomb Corp. announced that it will publish its first‑quarter 2026 financial results on April 29, with a live investor conference call at 8 a.m. ET. The webcast and dial‑in details are provided, and a replay will be accessible through...
Prilenia and Ferrer Announce First Participant Enrolled in the “PREVAiLS” Phase 3 Study of Pridopidine in ALS
Prilenia Therapeutics and Ferrer have enrolled the first participant in PREVAiLS, a pivotal Phase 3, 500‑patient, randomized, placebo‑controlled trial of the sigma‑1 receptor agonist pridopidine for rapidly progressive ALS. The study, launched at Mass General Brigham, will span 48 weeks with...
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform
Meiji Seika Pharma announced a strategic investment in U.S. biotech Centivax to accelerate its universal influenza vaccine, Centi‑Flu 01, currently in Phase 1 trials. The partnership leverages Meiji’s pharmaceutical expertise and Centivax’s computational immune‑engineering platform to target conserved viral regions, aiming for...
Biocytogen Grants Taisho Pharmaceutical a License to Its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform
Biocytogen has licensed its RenNano® fully human heavy‑chain‑only antibody discovery platform to Japan’s Taisho Pharmaceutical, granting access to RenNano mice for in‑vivo generation and screening of VHH candidates. The agreement, whose financial terms remain undisclosed, adds to Biocytogen’s expanding portfolio...
Advanced eClinical Training Partners with Emory University’s HeartStart Program to Deliver Medical Assistant Training for Pre-Medical Students
Advanced eClinical Training (ACT) has partnered with Emory University’s HeartStart program to launch a customized Clinical Medical Assistant (CCMA) training pathway for pre‑medical students. The inaugural cohort will include 50 learners who will receive certification preparation, simulation‑based patient‑care training, and...
Springfield Facility Expansion Marks Key Growth Milestone for Alltrista
Alltrista Plastics, a Jadex Inc. subsidiary, announced a 25,000‑square‑foot expansion of its Springfield, Missouri plant, slated for completion in September 2026. The multimillion‑dollar project will add new jobs and increase output for its medical and consumer packaging lines. The upgraded...
LiftWell Health Announces Brand Consolidation, Board & Presidential Appointment, In-Network Expansion, and Strategic Advisory Board
LiftWell Health merged Lift Wellness Group and LiftWell under a single brand, unveiling a new website to present a unified clinical vision across Connecticut and the broader Northeast. The organization appointed Awstin Gregg, MBA, LCSW‑S, LCDC, as President and Board...
New Nature-Published Research Reviews How Metabolic Dysfunction May Be Core Driver in Psychiatric Diseases
A new review in Nature Mental Health, led by Stanford’s Dr. Shebani Sethi, consolidates evidence from 138 studies that metabolic dysfunction is a central driver of schizophrenia, bipolar disorder, and major depression. The paper argues that impaired energy metabolism, not...
Kardigan Announces Positive Phase 2 Data for Tonlamarsen in Patients with Uncontrolled Hypertension Presented as Late-Breaker at ACC.26 and Simultaneously...
Kardigan reported positive Phase 2 data for its antisense drug tonlamarsen in the KARDINAL trial, showing a dose‑dependent 67% reduction in plasma angiotensinogen and a mean 6.7 mmHg drop in office systolic blood pressure after 20 weeks. Both a single 90 mg dose...
Arrowhead Pharmaceuticals Presents New Long-Term Efficacy and Safety Data for Plozasiran Across a Spectrum of Hypertriglyceridemia at the American College...
Arrowhead Pharmaceuticals presented two‑year open‑label extension data for plozasiran at the ACC 75th session, showing an 83% median triglyceride reduction in severe hypertriglyceridemia and 96% of patients dropping below the 500 mg/dL pancreatitis threshold. No adjudicated acute pancreatitis events occurred, and...
Open Label Outpatient Switch Study Demonstrates Symptom Stability During Transition From Oral Atypical Antipsychotics to Cobenfy™ (Xanomeline and Trospium Chloride)
Bristol Myers Squibb reported Phase 4 data showing that adults with schizophrenia can switch from oral atypical antipsychotics to Cobenfy (xanomeline‑trospium) without loss of symptom control. In an 8‑week open‑label trial, 86% of 105 patients completed the study, and mean PANSS...
IVF Academy USA Launches Accelerated Program to Help OBGYNs Bring Fertility Services Into Their Practices
IVF Academy USA unveiled a 30‑hour hybrid OBGYN Clinic‑Ready Fertility Services Accelerator, blending 14 hours of online coursework with a two‑day hands‑on residency. The program equips board‑certified OBGYNs to deliver in‑office fertility evaluations, IUI, and diagnostic hysteroscopy, complete with billing...
Banner|Aetna Brings Community Together for 2026 Phoenix Heart Walk
Banner | Aetna, the Arizona health‑plan joint venture of Banner Health and Aetna, is participating in the 2026 Phoenix Heart Walk as a member of the event’s Executive Leadership Team. CFO Dan Keller volunteers his time, highlighting a personal connection to heart...
Mochi Health and Livelong Women’s Health Summit Partner to Advance Women’s Metabolic Health
Mochi Health announced its role as a Premiere Sponsor of the Livelong Women’s Health Summit, scheduled for April 17‑18 in San Francisco. Founder and CEO Myra Ahmad, M.D., will headline a session on GLP‑1 medications and host a roundtable on...
LEO Pharma Announces New Long-Term Data for SPEVIGO® (Spesolimab-Sbzo) Injection in Adults with Generalized Pustular Psoriasis at AAD 2026
LEO Pharma presented long‑term results from the five‑year EFFISAYIL ON extension, showing subcutaneous SPEVIGO® reduced generalized pustular psoriasis (GPP) flares from an average of two per year to 0.13, with 74.6% of patients experiencing no flares over three years. Intravenous SPEVIGO...
VIVAZEN® Urges Immediate Action on 7-OH as U.S. House of Representatives Examines End Needless Distribution of 7-OH Act
VIVAZEN® welcomed a House Energy and Commerce subcommittee hearing on H.R. 8000, the End Needless Distribution of 7‑OH Act, urging the DEA to promptly schedule the synthetic opioid 7‑hydroxymitragynine. The company highlighted public‑health risks such as toxicity, dependence and market confusion...
FranklinCovey Provides Customized Solutions for Healthcare Organizations to Solve Key Issues: Nurse Retention and Patient Satisfaction
FranklinCovey is teaming with hospital leaders to boost nurse retention and patient satisfaction through customized leadership and trust programs. Documented results include moving patient‑satisfaction percentiles from the 26th to the 76th in four months and cutting leadership turnover by half...
Agenus to Host March 2026 Stakeholder Webcast Harnessing the Immune System to Advance BOT + BAL Across Tumor Types and...
Agenus announced a March 31, 2026 stakeholder webcast to detail progress on its botensilimab and balstilimab (BOT + BAL) immunotherapy program. The company highlighted clinical durability across multiple tumor types, with roughly 1,200 patients treated with botensilimab and over 900 with balstilimab...
Pediatrix Expands Maternal Health Services in Tennessee in Partnership with Tennessee Maternal-Fetal Medicine
Pediatrix Medical Group announced a cash acquisition of Tennessee Maternal‑Fetal Medicine, adding four board‑certified MFM physicians and six advanced practice providers to its Nashville operations. The partnership expands Pediatrix’s presence to five Greater Nashville locations, enhancing access to high‑risk obstetric...
Alpha Cognition Inc. Reports Fiscal 2025 Financial Results and Provides Operational Update
Alpha Cognition reported fourth‑quarter 2025 revenue of $2.5 million from its Alzheimer’s drug ZUNVEYL, bringing full‑year revenue to about $10.2 million. The company added a second national PBM contract, expanding coverage to two of the four major long‑term‑care payers, and saw prescriber...
GetHealthy Launches Script, an AI-Enabled Platform Expanding Practitioner Commerce Beyond Supplements Across Seven Product Categories
GetHealthy unveiled Script, an AI‑enabled clinical scripting platform that lets health practitioners prescribe comprehensive protocols across seven product categories, from supplements to pet health and diagnostic testing. The solution taps a catalog of over 400 vetted brands and integrates with...
AI-Powered Virtual Oncology Gets Smarter: Reimagine Care Advances Remi to Capture the Nuance of Cancer Patient Conversations
Reimagine Care announced a major upgrade to its AI‑powered virtual oncology assistant, Remi, shifting from rule‑based scripts to natural‑language understanding that can interpret complex patient messages. The SMS‑based platform now adds safety guardrails, AI‑assisted clinician summaries, and expanded monitoring for...
U.S. FDA Approves Label Update to Accelerate Thaw Time for ADSTILADRIN® (Nadofaragene Firadenovec-Vncg)
The U.S. FDA has approved a label update for Ferring Pharmaceuticals' ADSTILADRIN® (nadofaragene firadenovec‑vncg) that permits an accelerated water‑bath thawing process completed in roughly 25 minutes. The therapy, the only FDA‑approved non‑replicating intravesical gene‑therapy for high‑risk BCG‑unresponsive non‑muscle invasive bladder...
Phreesia Named One of Becker’s Top Places to Work in Healthcare
Phreesia has been named one of Becker’s Healthcare Top Places to Work for 2026, marking its second appearance on the prestigious list. The accolade recognizes the company’s fully remote structure, competitive compensation, flexible time off, home‑office support, generous parental benefits...
Mark Farrah Associates’ Health Coverage Portal Simplifies Health Insurance Data Analytics
Mark Farrah Associates (MFA) has released its 2025 health‑plan data through the Health Coverage Portal™. The portal aggregates statutory financial statements from the NAIC and California DMHC, offering enrollment, market‑share, revenue, expense, and loss‑ratio metrics for individual, group, ASO and...
Impact Podcast with John Shegerian Features Special Two-Part, In-Depth Interview with Dr. Dawn Mussallem
Dr. Dawn Mussallem, newly appointed chief medical officer of longevity firm Fountain Life, appears in a two‑part interview on the Impact Podcast with John Shegerian. The episode highlights her personal survival story—from a stage IV cancer diagnosis and a 2021 heart...
Prestige Medical Group Announces New Woodstock Location, Expanding Access to Care in Cherokee County
Prestige Medical Group, a physician‑led network serving North Georgia for over two decades, opened a new office in Woodstock, Georgia on March 24, 2026. The 102 Springfield Center Drive clinic provides primary care and pediatric services five days a week and also...
KeyCare Deploys NVIDIA Nemotron to Power AI-Driven Clinical Intake at Scale
KeyCare, the nation’s only Epic‑based virtual care group, has launched NVIDIA’s Nemotron large language model in production to power its AI‑driven patient intake agent. The agent, embedded in KeyCare’s virtual waiting room, captures and summarizes clinically relevant Epic data before...
Alnylam Advances Future of ATTR-CM Care Through Strategic Collaboration with Viz.ai and Support for the American Heart Association
Alnylam Pharmaceuticals announced a strategic partnership with Viz.ai to develop an AI‑enabled care pathway for earlier detection of transthyretin amyloid cardiomyopathy (ATTR‑CM), launching the AWARE study in five health systems. The company also pledged support for the American Heart Association’s...
OnMed Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2026
OnMed has been named to Fast Company’s World’s Most Innovative Companies list for 2026, earning a No. 14 ranking in North America. The company’s AI‑enabled CareStation™ platform has expanded into rural states, schools, an airport hub, and Puerto Rico over the...
Amylyx Pharmaceuticals Announces Completion of Enrollment in Pivotal Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia
Amylyx Pharmaceuticals announced that the pivotal Phase 3 LUCIDITY trial of avexitide has completed enrollment, randomizing and dosing the final participant to bring the total to 78 patients across 21 U.S. sites. The double‑blind, placebo‑controlled study evaluates avexitide, a first‑in‑class GLP‑1...
Experian Health’s 2026 State of Patient Access Survey Reveals Patient Experience Is Improving, but Big Challenges Remain for Healthcare Providers
Experian Health’s 2026 State of Patient Access Survey shows modest gains in perceived access, with 46% of providers saying access improved versus only 18% of patients. Operational efficiencies and digital tools are helping, but staffing shortages now affect 64% of...
Mosaic Therapeutics to Present Poster Highlighting Preclinical Data for Lead Program MOS101 at the American Association for Cancer Research (AACR)...
Mosaic Therapeutics will present preclinical data on its lead program MOS101—a combination of the next‑generation MDM2 antagonist ASTX295 and the FDA‑approved PARP inhibitor olaparib—at the AACR 2026 Annual Meeting. The poster focuses on BRCA2‑mutant, TP53‑wild‑type solid tumours and highlights the...
Palm Primary Care Expands in Tarrant County with Acquisition of Two Clinics in Azle
Palm Primary Care, backed by MBF Healthcare Partners II, has acquired two primary‑care clinics in Azle, Texas, expanding its Texas network to nine locations across Tarrant and Dallas counties. The two sites, Azle Central and Azle Parkway, will continue operating...
Integrated DNA Technologies Expands Into Clinical Diagnostics with First In Vitro Diagnostic
Integrated DNA Technologies (IDT) announced the launch of two in‑vitro diagnostic kits, Archer FUSION Plex‑HT Dx and VARIANT Plex‑HT Dx, marking its entry into the next‑generation sequencing (NGS) IVD market. Built on IDT’s proprietary anchored multiplex PCR chemistry, the kits offer targeted DNA and RNA...
Matrix Providers Inc. Announces Leadership Transition: Founder Dr. Bill Rivard to Become Chairman; Tricia Brown Named CEO
Matrix Providers Inc. announced that founder and CEO Dr. Bill Rivard will become Chairman of the Board on April 1, 2026, while President and COO Tricia Brown will step up as President and CEO. Rivard, who founded the company in...
Cencora to Expand Retina Consultants of America Through Acquisition of EyeSouth Partners’ Retina Business
Cencora, Inc. announced a definitive agreement to acquire EyeSouth Partners’ retina business for $1.1 billion, integrating the physicians into its Retina Consultants of America (RCA) network. The acquisition is expected to be slightly accretive to adjusted diluted EPS within the first...
Oryon Cell Therapies Reports Phase 1b/2a Data Showing Sustained Motor Improvements in People with Parkinson’s Disease
Oryon Cell Therapies presented interim Phase 1b/2a data showing that its autologous dopaminergic neuron‑replacement therapy produced sustained motor improvements in Parkinson’s patients. Five participants experienced 29‑62% reductions in OFF‑state MDS‑UPDRS Part III scores over 6‑18 months, with continued gains beyond six months....
Latent-Y: The Autonomous AI Agent for Drug Design at Scale
Latent Labs unveiled Latent‑Y, an autonomous AI agent that designs therapeutic antibodies from natural‑language prompts. Powered by the Latent‑X2 generative model, the platform compresses weeks of expert work into hours and can run multiple design campaigns in parallel. In three...
Almirall’s 17th Skin Academy Highlights Scientific Advances in Inflammatory Skin Diseases and Skin Cancer, Patient-Reported Outcomes, and Holistic Care in...
Almirall hosted its 17th Skin Academy in Barcelona and Prague, drawing 800 dermatology professionals to discuss the latest science in medical dermatology. The program spotlighted new insights into atopic dermatitis—especially facial and neck involvement—and psoriasis, emphasizing patient‑reported outcomes and holistic...
Galderma Receives U.S. FDA Approval for Restylane® Contour™ for the Correction of Temple Hollowing
Galderma announced that the U.S. FDA has cleared Restylane Contour for the correction of temple hollowing in adults over 21, extending its existing cheek and mid‑face indications. Clinical studies demonstrated a 91% responder rate at three months, with efficacy persisting for...
Prothena Partners Present Data Supporting Next Generation Treatments for Parkinson’s and Alzheimer’s Disease at AD/PD™ 2026
Prothena and its partners Roche and Bristol Myers Squibb presented late‑stage data on two neurodegenerative candidates at AD/PD™ 2026. Prasinezumab demonstrated a roughly two‑year delay in Parkinson’s disease progression, sustained motor benefits in the PADOVA open‑label extension, and favorable imaging and...
ImmunityBio Announces Approval in Macau SAR, China for ANKTIVA® in BCG-Unresponsive NMIBC with CIS ± Papillary Tumors
ImmunityBio secured its first Asian regulatory clearance as the Macau Special Administrative Region approved ANKTIVA® for BCG‑unresponsive non‑muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The decision leveraged prior FDA and EMA approvals, illustrating a...
Health Gorilla and GuardDog Telehealth Set the Record Straight
Health Gorilla released a case study and 21 recorded meetings showing GuardDog consistently described its services as treatment‑focused telehealth. The materials confirm GuardDog’s claim that all data queries were made under HIPAA authorizations to support patient care, not for non‑treatment...
Fauna Bio Announces Target Designation Milestone in Obesity Discovery Collaboration
Fauna Bio announced that its Convergence™ AI platform has achieved a target designation milestone in its obesity discovery partnership with Eli Lilly, triggering a contractual payment. The designated target stems from comparative genomics of over 450 mammal species, especially hibernators,...
Glaukos Announces Commercial Availability of Epioxa™, a Transformative Innovation in Interventional Keratoconus Care
Glaukos announced that Epioxa™ HD/Epioxa™ is now commercially available, marking the first FDA‑approved, incision‑free topical drug for keratoconus. The therapy uses a riboflavin solution with the O₂n™ System and Boost Goggles, eliminating the need to remove the corneal epithelium. By...
TALZENNA Plus XTANDI Significantly Improves Radiographic Progression-Free Survival in Metastatic Prostate Cancer
Pfizer announced that the Phase 3 TALAPRO‑3 trial met its primary endpoint, showing that TALZENNA (talazoparib) combined with XTANDI (enzalutamide) significantly improved radiographic progression‑free survival (rPFS) in patients with HRR gene‑mutated metastatic hormone‑sensitive prostate cancer. The combination achieved a hazard ratio...
